Search

Search Constraints

You searched for: Author/Creator Wheeler, David C

Search Results

11. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. Issue 11 (November 2020)

12. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. (23rd August 2021)

13. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Issue 1 (January 2021)

14. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. (1st April 2021)

15. Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease. Issue 7 (11th May 2018)

17. FC 063DAPAGLIFLOZIN DECREASES ALBUMINURIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH AND WITHOUT TYPE 2 DIABETES: INSIGHTS FROM THE DAPA-CKD TRIAL. (29th May 2021)

19. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Issue 10105 (21st October 2017)